



US006350466B1

(12) **United States Patent**
Li et al.

(10) **Patent No.:** **US 6,350,466 B1**
(45) **Date of Patent:** ***Feb. 26, 2002**

(54) **TARGETED POLYMERIZED LIPOSOME
DIAGNOSTIC AND TREATMENT AGENTS**

4,544,545 A 10/1985 Ryan et al.
4,784,912 A 11/1988 Schaeffer et al.

(75) Inventors: **King Chuen Li**, Stanford; **Mark David Bednarski**, Los Altos; **Richard Wood Storrs**, San Diego; **Henry Y. Li**, Visalia, all of CA (US); **Francois Daniel Tropper**, Toronto (CA); **Curtis Kang Hoon Song**, Sunnyvale, CA (US); **Dorothy Anna Sipkins**, Palo Alto, CA (US); **Jeremy Kenji Kuniyoshi**, Cupertino, CA (US)

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

JP	63054384	3/1988
WO	WO92/21017	11/1992
WO	WO97/31625	9/1997

OTHER PUBLICATIONS

Archelos et al. (1993) Ann. Neurology 34(2):145-154
Inhibition of Experimental Autoimmune Encephalomyelitis by an Antibody to the Intercellular Adhesion Molecule ICAM-1.

Charych et al. (1996) Chem Tech 24-28, Artificial cell membranes for diagnostics and therapeutics.

Charych et al. (1993) Science 261:585-589, Direct colorimetric detection of a receptor-ligand interaction by a polymerized bilayer assembly.

Hannan (1995) Arch. Pathol Lab. Med. 119:890-893 Future Practices in Diagnostic Medicine.

(73) Assignee: **Targesome, Inc.**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/650,276**

(List continued on next page.)

(22) Filed: **Aug. 29, 2000**

Related U.S. Application Data

(63) Continuation of application No. 08/629,056, filed on Apr. 8, 1996, now Pat. No. 6,132,764, which is a continuation-in-part of application No. 08/286,555, filed on Aug. 5, 1994, now Pat. No. 5,512,294.

(51) **Int. Cl.**⁷ **A61K 9/127**

(52) **U.S. Cl.** **424/450**; 424/1.21; 424/9.321;
424/9.51; 424/94.3; 424/812; 436/829;
935/54

(58) **Field of Search** 424/450, 1.21,
424/9.321, 9.51, 417, 94.3, 812; 436/829;
935/54; 428/402.2

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,259,313 A 3/1981 Frank et al.

Primary Examiner—Gollamudi S. Kishore

(74) *Attorney, Agent, or Firm*—Swanson & Bratschun, LLC

(57) **ABSTRACT**

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

23 Claims, 25 Drawing Sheets

